These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 7590500)

  • 41. Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.
    De Lena M; Maiello E; Lorusso V; Brandi M; Calabrese P; Romito S; Mazzei A; Marzullo F
    Med Oncol Tumor Pharmacother; 1989; 6(2):163-9. PubMed ID: 2473364
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Long term results of treatment of highly-malignant non-Hodgkin lymphoma in the elderly (70 years and older)].
    Sonnen R; Kuse R
    Dtsch Med Wochenschr; 1998 Feb; 123(8):205-11. PubMed ID: 9526489
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas.
    Laurencet F; Ballabeni P; Rufener B; Hess U; Cerny T; Fey M; Luthi JM; Plancherel C; Zulian GB;
    Acta Haematol; 2007; 117(1):40-7. PubMed ID: 17095858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
    Fridrik MA; Hausmaninger H; Linkesch W; Stöger M; Sill H; Neubauer M; Seewann HL; Klocker J; Haidinger R; Schiller L; Pont J; Raudaschl G; Falk M; Radaszkiewicz T
    J Clin Oncol; 1996 Jan; 14(1):227-32. PubMed ID: 8558202
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
    Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
    Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
    Bertini M; Freilone R; Vitolo U; Botto B; Pizzuti M; Gavarotti P; Levis A; Orlandi E; Orsucci L; Pini M
    Ann Oncol; 1994 Dec; 5(10):895-900. PubMed ID: 7535080
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphomas in children and adolescents. Part 2: An intermediate term analysis of the non-B-NHL therapy group. BFM Study group].
    Reiter A; Schrappe M; Yakisan E; Sauter S; Henzler D; Zimmermann M; Graf N; Fengler R; Kühl J; Fleischhack G
    Klin Padiatr; 1994; 206(4):234-41. PubMed ID: 7967419
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma.
    Bishop JF; Wiernik PH; Wesley MN; Kaplan RS; Diggs CH; Barcos MP; Sutherland JC
    Leukemia; 1987 Jun; 1(6):508-13. PubMed ID: 3669768
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy and radiotherapy for stage I intermediate or high grade non-Hodgkin's lymphomas: results of a strategy that adapts radiotherapy dose to the response after chemotherapy.
    Krol AD; Berenschot HW; Doekharan D; Henzen-Logmans S; van der Holt B; van 't Veer MB
    Radiother Oncol; 2001 Mar; 58(3):251-5. PubMed ID: 11230885
    [TBL] [Abstract][Full Text] [Related]  

  • 51. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
    Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
    Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epidoxorubicin vs idarubicin containing regimens in intermediate and high grade non-Hodgkin's lymphoma: preliminary results of a multicentric randomized trial.
    Brugiatelli M; Federico M; Gobbi PG; Avanzini P; Callea V; Cavanna L; De Pasquale A; Di Prisco AU; Di Rienzo N; Silingardi V
    Haematologica; 1993; 78(5):306-12. PubMed ID: 8314160
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined modality treatment with primary CHOP chemotherapy followed by locoregional irradiation in stage I or II histologically aggressive non-Hodgkin's lymphomas.
    Tondini C; Zanini M; Lombardi F; Bengala C; Rocca A; Giardini R; Buzzoni R; Valagussa P; Bonadonna G
    J Clin Oncol; 1993 Apr; 11(4):720-5. PubMed ID: 8478665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
    Peters FP; Fickers MM; Erdkamp FL; Wals J; Wils JA; Schouten HC
    Ann Hematol; 2001 Jul; 80(7):406-10. PubMed ID: 11529466
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
    Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
    Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.
    Meyer RM; Browman GP; Samosh ML; Benger AM; Bryant-Lukosius D; Wilson WE; Frank GL; Leber BF; Sternbach MS; Foster GA
    J Clin Oncol; 1995 Sep; 13(9):2386-93. PubMed ID: 7666098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study.
    Yahalom J; Varsos G; Fuks Z; Myers J; Clarkson BD; Straus DJ
    Cancer; 1993 Apr; 71(7):2342-50. PubMed ID: 8453557
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Tunisian experience in the treatment of aggressive non Hodgkin's lymphoma in adults: about 337 patients].
    Laatiri MA; Elloumi M; Ali ZB; Ben Othmen T; Msadek F; Toumi N; Bouaouina N; Daoud J; Maalej M; Ghannem H; Meddeb B
    Bull Cancer; 2010 Apr; 97(4):409-16. PubMed ID: 20374978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.